-
Hotel Blacklist Launches New Accommodation Industry Risk Assessment Tool
-
Messi says Argentina retirement is 'saddest day of my career'
-
Bangladesh nuclear plant draws hope -- and worry
-
Oil rises and stocks fall as Hormuz worries flare
-
US beat Canada 1-0 to wrap up four-win international break
-
Pacific presses world for help 'surviving' climate change at pre-COP summit
-
Turkey, Australia's joint COP31 leadership raises doubts
-
Verstappen revival to be put to the test in steamy Singapore
-
For Turkish NGOs, COP31 offers rare space for action
-
US woman who survived botched execution is conscious, speaking: lawyers
-
Sleep, appetite, gene-editing experts contend for Nobel chemistry prize
-
Climate champion Australia digging more coal
-
Nobel Peace Prize haunted by the 'spectre' of Trump
-
Emotion, tears as Messi retires from Argentina national team
-
Africa launches own credit agency in bid for cheaper borrowing
-
Dodgers push Braves to the brink of MLB playoff exit
-
US, China, EU: three paths to regulating AI
-
Crisis-stricken Haiti postpones elections
-
Australia's High Court rules against coal mine in landmark climate case
-
N. Korea's Kim pledges 'invariable support' in Putin birthday letter
-
Australia touts new funds for Pacific infrastructure at Fiji 'pre-COP'
-
OGRD Alliance Advances PLPC Multi-Asset Platform Following APHELAR Milestone, Expanding Licensing and Strategic Capital Frameworks
-
Eva Marie Saint, Oscar winner of Hollywood classics, dies at 102
-
Emotion, tears as Messi prepares for Argentina farewell
-
Australia probes app used in cheap smart glasses over privacy fears
-
Kane eyes Ronaldo record after matching England cap mark
-
England needed to 'move on' from World Cup pain, says Tuchel
-
Spain fight back to beat Croatia, Kane adds to record for England
-
O'Neill to stay at Celtic after period of "reflection"
-
Merino double helps Spain beat Croatia, reach Nations League quarters
-
Kane marks 125th England cap with Wembley Nations League double
-
US stocks hit fresh records as oil stabilizes on rising supplies
-
Quebec's incoming separatist leader wants to block Crown from swearing-in
-
As Messi bows out, Argentines say 'thank you'
-
Emmys gala will now stream its premier television awards
-
Ronaldo opens door for Portugal return, apologises for walkout
-
Paramount completes Warner Bros takeover, creating Skydance
-
'Nobody seems to care': Russian city shrugs off plague reports
-
Trump blames France unrest on Islam, migration
-
Hundreds arrested in French school protests as Macron summons ministers
-
Apple's Cook praises EU over efforts to protect children online
-
WADA seeks tough anti-doping stance from Kenya
-
Nobel winner Halzen says years of October 'misery' finally over
-
German ex-spy chief arrested for suspected espionage, treason
-
Quebec separatist win rattles Carney's unity push
-
Furyk vows US will 'do more' to end Ryder Cup losing streak
-
'Itching' for change: Shiffrin cuts back slaloms this season
-
Iyer hits ton as India hammer West Indies in T20 opener
-
'Gen Z has risen up': Tens of thousands mass for tense France school protests
-
Mandhana named India women's team captain after Kaur quits
Science of sleep: Why a good night's rest gets harder with age
It's well known that getting a good night's sleep becomes more difficult as we age, but the underlying biology for why this happens has remained poorly understood.
A team of US scientists has now identified how the brain circuitry involved in regulating sleepfulness and wakefulness degrades over time in mice, which they say paves the way for better medicines in humans.
"More than half of people 65 and older complain about the quality of sleep," Stanford University professor Luis de Lecea, who co-authored a study about the finding published Thursday in Science, told AFP.
Research has shown that sleep deprivation is linked to an increased risk of multiple poor health outcomes, from hypertension to heart attacks, diabetes, depression and a build up of brain plaque linked to Alzheimer's.
Insomnia is often treated with a class of drugs known as hypnotics, which include Ambien, but these don't work very well in the elderly population.
For the new study, de Lecea and colleagues decided to investigate hypocretins, key brain chemicals that are generated only by a small cluster of neurons in the brain's hypothalamus, a region located between the eyes and ears.
Of the billions of neurons in the brain, only around 50,000 produce hypocretins.
In 1998, de Lecea and other scientists discovered that hypocretins transmit signals that play a vital role in stabilizing wakefulness.
Since many species experience fragmented sleep as they grow old, it's hypothesized that the same mechanisms are at play across mammals, and prior research had shown degradation of hypocretins leads to narcolepsy in humans, dogs and mice.
The team selected young (three to five months) and old mice (18 to 22 months) and used light carried by fibers to stimulate specific neurons. They recorded the results using imaging techniques.
What they found was that the older mice had lost approximately 38 percent of hypocretins compared to younger mice.
They also discovered that the hypocretins that remained in the older mice were more excitable and easily triggered, making the animals more prone to waking up.
This might be because of the deterioration over time of "potassium channels," which are biological on-off switches critical to the functions of many types of cells.
"The neurons tend to be more active and fire more, and if they fire more, you wake up more frequently," said de Lecea.
Identifying the specific pathway responsible for sleep loss could lead to better drugs, argued Laura Jacobson and Daniel Hoyer, of Australia's Florey Institute of Neuroscience and Mental Health, in a related commentary article.
Current treatments, such as hypnotics, "can induce cognitive complaints and falls," and medicines that target the specific channel might work better, they said.
These will need to be tested in clinical trials -- but an existing drug known as retigabine, which is currently used to treat epilepsy and which targets a similar pathway -- could be promising, said de Lecea.
Y.AlMasri--SF-PST